Protagonist Therapeutics PTGX Balance Sheet Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $193.71M+38.7% | $128.39M+32.0% | $113.71M-13.3% | $168.54M-52.6% | $139.65M-19.1% | ||
| $354.07M-18.5% | $438.97M+36.5% | $462.4M+37.0% | $401.92M+92.9% | $434.71M+190% | ||
| $613.46M+1.3% | $577.57M-2.4% | $586.42M+23.0% | $602.53M+5.5% | $605.86M-3.5% | ||
| $3.78M+7.0% | $3.86M+21.0% | $4.1M+66.1% | $4.11M+131% | $3.53M+218% | ||
| $697.46M-6.0% | $668.19M-10.3% | $701.69M+16.2% | $718.01M+16.8% | $742.13M+17.9% | ||
| $6.28M— | $9.55M— | $2.79M— | —— | —— | ||
| $34.55M-1.6% | $45.44M-4.1% | $44.94M+0.8% | $35.51M-14.6% | $35.11M-12.0% | ||
| $41.99M-20.9% | $53.48M-23.0% | $56.25M-21.8% | $49.99M-31.8% | $53.08M-22.9% | ||
| $1K0.0% | $1K0.0% | $1K0.0% | $1K0.0% | $1K0.0% | ||
| -$466.89M-32.6% | -$470.67M-38.2% | -$426.29M+9.7% | -$386.95M+11.9% | -$352.18M+13.8% | ||
| $655.47M-4.9% | $614.71M-9.0% | $645.44M+21.3% | $668.02M+23.4% | $689.05M+22.9% | ||
| $697.46M-6.0% | $668.19M-10.3% | $701.69M+16.2% | $718.01M+16.8% | $742.13M+17.9% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Protagonist Therapeutics's total assets?
- Protagonist Therapeutics (PTGX) holds $697.5M in total assets, down 6.0% year over year.
- How much debt does Protagonist Therapeutics have?
- Protagonist Therapeutics carries $9.8M in total debt against $655.5M of shareholders' equity, a debt-to-equity ratio of 0.01.
- How much cash does Protagonist Therapeutics have?
- Protagonist Therapeutics holds $193.7M in cash and equivalents.
- Can Protagonist Therapeutics cover its short-term obligations?
- Its current ratio is 17.76 — current assets exceed current liabilities.
- Where does Protagonist Therapeutics's balance sheet data come from?
- Every line is extracted from Protagonist Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
